Keba Biological

Keba Biological is a Chinese biotechnology company focused on the development of innovative oncolytic virus therapies for the treatment of cancer. The company's core technology involves recombinant human adenoviruses engineered to selectively target and destroy tumor cells while stimulating a systemic anti-tumor immune response. Its lead candidate, KH901, is an oncolytic adenovirus expressing GM-CSF, which has been investigated in clinical trials for head and neck cancers. Following its acquisition by Chengdu Kanghong Pharmaceutical Group, Keba Biological serves as a key research and development unit for the parent company's biologics and gene therapy pipeline. The company represents an early pioneer in the Chinese biotech landscape, specifically within the field of viral immunotherapy.